(RVP) Retractable Technologies - Ratings and Ratios
Exchange: NYSE MKT • Country: United States • Currency: USD • Type: Common Stock • ISIN: US76129W1053
RVP: Syringes, Needles, Catheters, Adapters, Trays, Collection Sets
Retractable Technologies, Inc. (NYSE MKT: RVP) is a U.S.-based developer and manufacturer of safety medical products, primarily focusing on syringes and catheters designed to reduce the risk of needlestick injuries. The company offers a diverse range of products, including VanishPoint insulin syringes, tuberculin and allergy antigen syringes, blood collection tube holders, IV safety catheters, and autodisable syringes. These products are distributed through a network of general and specialty distributors, international partners, and direct marketing channels. Headquartered in Little Elm, Texas, Retractable Technologies has been operational since its incorporation in 1994 and serves healthcare professionals across the Americas and internationally. The companys product portfolio emphasizes safety, convenience, and compliance with regulatory standards in the medical industry.
Based on the provided technical and fundamental data, the 3-month forecast for Retractable Technologies, Inc. (RVP) is as follows: - Technical Outlook: RVP is currently trading below its 20-day and 50-day Simple Moving Averages (SMA), indicating potential weakness in the short term. The 200-day SMA of 0.86 suggests resistance at higher levels. Average True Range (ATR) of 0.05 signals low volatility, implying narrow price fluctuations in the near term. - Fundamental Outlook: With a market capitalization of $17.55 million and a negative Return on Equity (RoE) of -18.85%, RVP faces challenges in profitability. The low Price-to-Book (P/B) ratio of 0.29 and Price-to-Sales (P/S) ratio of 0.58 may indicate undervaluation, but the lack of positive earnings (P/E: 0.00) raises concerns about growth prospects. - Forecast: Over the next three months, RVP is expected to trade in a range-bound manner with limited upside potential. The stock may test support near its current levels or slightly lower, while resistance is likely to cap gains at the 200-day SMA of 0.86. Investors should monitor volume trends and any potential catalysts for a breakout or breakdown from the current range.
Additional Sources for RVP Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
RVP Stock Overview
Market Cap in USD | 18m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Health Care Supplies |
IPO / Inception | 2001-05-04 |
RVP Stock Ratings
Growth 5y | -56.4% |
Fundamental | -42.9% |
Dividend | 0.0% |
Rel. Strength Industry | -39 |
Analysts | - |
Fair Price Momentum | 0.66 USD |
Fair Price DCF | 1.48 USD |
RVP Dividends
No Dividends PaidRVP Growth Ratios
Growth Correlation 3m | 50.1% |
Growth Correlation 12m | -78% |
Growth Correlation 5y | -87.3% |
CAGR 5y | -7.35% |
CAGR/Max DD 5y | -0.08 |
Sharpe Ratio 12m | 1.04 |
Alpha | -47.11 |
Beta | 0.68 |
Volatility | 58.14% |
Current Volume | 19.3k |
Average Volume 20d | 47.1k |
As of March 16, 2025, the stock is trading at USD 0.75 with a total of 19,347 shares traded.
Over the past week, the price has changed by -1.03%, over one month by -5.99%, over three months by +15.43% and over the past year by -38.50%.
Probably not. Based on ValueRay Fundamental Analyses, Retractable Technologies (NYSE MKT:RVP) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -42.86 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RVP as of March 2025 is 0.66. This means that RVP is currently overvalued and has a potential downside of -12%.
Retractable Technologies has no consensus analysts rating.
According to ValueRays Forecast Model, RVP Retractable Technologies will be worth about 0.7 in March 2026. The stock is currently trading at 0.75. This means that the stock has a potential downside of -2.67%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 0.7 | -2.7% |